Company profile
Guardant Health, Inc.
NASDAQ: GH · Healthcare · Medical - Diagnostics & Research
#156 of 1,418 Healthcare companies by revenue73rd-percentile growth
EA Score
65BFH 60DQ 62GM 81SS 75
v0.1 · 65/100 weight · provisional
↑ market scale, growth stability · ↓ balance-sheet leverage, listing tenure
Methodology →Revenue TTM
$1.1B
Rev growth YoY (TTM)
+39.6%
Net income (FY)
-$416.3M
Employees
2,506
as of 2026-08-05
Market cap
$21.4B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$982.0M$982.0M2025
Net income-$416.3M-$416.3M2025
Operating income-$437.2M-$437.2M2025
Total assets$2.0B$2.0B2025
Liabilities$2.1B$2.1B2025
Equity-$99.3M-$99.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Oncology70%
Biopharma & Data21%
Screening8%
Licensing & Other1%
By geography
UNITED STATES94%
Non-US6%
The read
What is Guardant Health, Inc.’s revenue?
Guardant Health, Inc. booked $982.0M in FY2025 revenue, growing 33% year over year — faster than most Healthcare companies we track, at a -42.4% net margin.
Peers · Healthcare
Bone Biologics Corporation45DTandem Diabetes Care, Inc.67BWELL Health Technologies Corp.71BClaritev Corporation61CMadrigal Pharmaceuticals, Inc.64CThe Pennant Group, Inc.73BNeighbors
Santa Clara →Key facts
CEOHelmy Eltoukhy
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersPalo Alto, CA
ExchangeNASDAQ: GH
Employees2,506
IPO date2018-10-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.